Aggressive B-cell Lymphomas

doi:10.1017/9781009397797.006

Chapter 6 - Aggressive B-cell Lymphomas

from Section 1 - Mature B-cell and Plasma Cell Neoplasms

Published online by Cambridge University Press: 20 May 2026

Shaoying Li,

Jie Xu and

Lianqun Qiu

Edited by

Wei Wang and

Sa A. Wang

Show author details

Wei Wang: Affiliation:
The University of Texas MD Anderson Cancer Center
Sa A. Wang: Affiliation:
The University of Texas MD Anderson Cancer Center

Book contents

Get access

Summary

This chapter focuses on the flow cytometry immunophenotypic evaluation of Burkitt lymphoma, diffuse large B-cell lymphoma or high-grade B-cell lymphoma with MYC and BCL2 rearrangements (with or without BCL6 rearrangement), high-grade B-cell lymphoma not otherwise specified, and diffuse large B-cell lymphoma. The differential diagnosis among these three entities and with other entities is also discussed, with a focus on flow cytometry analysis. The differential diagnosis between surface light chain negatve blastoid high-grade B-cell lymphoma and CD34-negative B-ALL sometimes can be very challenge. Features that may be helpful for such a differential diagnosis, mostly flow cytometric immunophenotypic features, are discussed in detail.

Keywords

Burkitt lymphoma high-grade B-cell lymphoma not otherwise specified (HGBL NOS)diffuse large B-cell lymphoma (DLBCL)DLBCL/HGBL with MYC and BCL2 rearrangements blastoid HGBL B-ALL blastoid/pleomorphic mantle cell lymphoma flow cytometry MYC TdT

Information

Type: Chapter
Information: Flow Cytometry in Hematolymphoid Neoplasms
A Comprehensive and Practical Guide to Diagnosis
, pp. 51 - 62
DOI: https://doi.org/10.1017/9781009397797.006 [Opens in a new window]
Publisher: Cambridge University Press
Print publication year: 2026

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Kelemen, K, Braziel, RM, Gatter, K, Bakke, TC, Olson, S, Fan, G. Immunophenotypic variations of Burkitt lymphoma. Am J Clin Pathol 2010; 134: 127–138.10.1309/AJCP93LJPTRQPDKRCrossRef Google Scholar PubMed

Lin, CW, O’Brien, S, Faber, J, Manshouri, T, Romaguera, J, Huh, YO, et al. De novo CD5+ Burkitt lymphoma/leukemia. Am J Clin Pathol 1999; 112: 828–835.10.1093/ajcp/112.6.828CrossRef Google Scholar PubMed

Tomita, N, Takeuchi, K, Hyo, R, Hashimoto, C, Takemura, S, Taguchi, J, et al. Diffuse large B cell lymphoma without immunoglobulin light chain restriction by flow cytometry. Acta Haematol 2009; 121: 196–201.10.1159/000220332CrossRef Google Scholar PubMed

Thakral, B, Medeiros, LJ, Desai, P, Lin, P, Yin, CC, Tang, G, et al. Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH. Eur J Haematol 2017; 98: 415–421.10.1111/ejh.12847CrossRef Google Scholar PubMed

Maleki, A, Seegmiller, AC, Uddin, N, Karandikar, NJ, Chen, W. Bright CD38 expression is an indicator of MYC rearrangement. Leuk Lymphoma 2009; 50: 1054–1057.10.1080/10428190902930470CrossRef Google Scholar

Mandelker, DL, Dorfman, DM, Li, B, Pozdnyakova, O. Antigen expression patterns of MYC-rearranged versus non-MYC-rearranged B-cell lymphomas by flow cytometry. Leuk Lymphoma 2014; 55: 2592–2596.10.3109/10428194.2013.879714CrossRef Google Scholar PubMed

Wang, XJ, Medeiros, LJ, Lin, P, Yin, CC, Hu, S, Thompson, MA, Li, S. MYC cytogenetic status correlates with expression and has prognostic significance in patients with MYC/BCL2 protein double-positive diffuse large B-cell lymphoma. Am J Surg Pathol 2015; 39: 1250–1258.10.1097/PAS.0000000000000433CrossRef Google Scholar PubMed

Harrington, AM, Olteanu, H, Kroft, SH, Eshoa, C. The unique immunophenotype of double-hit lymphomas. Am J Clin Pathol 2011; 135: 649–650.10.1309/AJCPL11MAHISIJBQCrossRef Google Scholar PubMed

Roth, CG, Gillespie-Twardy, A, Marks, S, Agha, M, Raptis, A, Hou, JZ, et al. Flow cytometric evaluation of double/triple hit lymphoma. Oncol Res 2016; 23: 137–146.10.3727/096504015X14500972666761CrossRef Google Scholar PubMed

Wu, D, Wood, BL, Dorer, R, Fromm, JR. “Double-hit” mature B-cell lymphomas show a common immunophenotype by flow cytometry that includes decreased CD20 expression. Am J Clin Pathol 2010; 134: 258–265.10.1309/AJCP7YLDTJPLCE5FCrossRef Google Scholar PubMed

Alsuwaidan, A, Koduru, P, Fuda, F, Manuel Jaso, J, Chen, M, Rosado, F, et al. A combined biomarker of bright CD38 and MYC >/= 55% is highly predictive of double-/triple-hit high-grade B-cell lymphoma. Am J Clin Pathol 2022; 158: 338–344.10.1093/ajcp/aqac047CrossRef Google Scholar PubMed

Li, S, Qiu, L, Xu, J, Lin, P, Ok, CY, Tang, G, et al. High-grade B-cell lymphoma (HGBL)-NOS is clinicopathologically and genetically more similar to DLBCL/HGBL-DH than DLBCL. Leukemia 2023; 37: 422–432.10.1038/s41375-022-01778-9CrossRef Google Scholar PubMed

Ok, CY, Medeiros, LJ, Thakral, B, Tang, G, Jain, N, Jabbour, E, et al. High-grade B-cell lymphomas with TdT expression: A diagnostic and classification dilemma. Mod Pathol 2019; 32: 48–58.10.1038/s41379-018-0112-9CrossRef Google Scholar PubMed

Qiu, L, Wang, SA, Tang, G, Wang, W, Lin, P, Xu, J, et al. Blastoid B-cell neoplasms: Diagnostic challenges and solutions. Cancers (Basel) 2023; 15: 848. https://doi.org/10.3390/cancers15030848.CrossRef Google Scholar PubMed

Espasa, A, Tapia, G, Vergara, S, Raya, M, Junca, J, Sorigue, M. Flow cytometric expression of CD71, CD81, CD44 and CD39 in B cell lymphoma. Scand J Clin Lab Invest 2021; 81: 413–417.10.1080/00365513.2021.1929446CrossRef Google Scholar PubMed

Zhang, QY, Foucar, K. Bone marrow involvement by Hodgkin and non-Hodgkin lymphomas. Hematol Oncol Clin North Am 2009; 23: 873–902.10.1016/j.hoc.2009.04.014CrossRef Google Scholar PubMed

Chung, R, Lai, R, Wei, P, Lee, J, Hanson, J, Belch, AR, et al. Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index. Blood 2007; 110: 1278–1282.10.1182/blood-2007-01-070300CrossRef Google Scholar

Kremer, M, Spitzer, M, Mandl-Weber, S, Stecker, K, Schmidt, B, Hofler, H, et al. Discordant bone marrow involvement in diffuse large B-cell lymphoma: Comparative molecular analysis reveals a heterogeneous group of disorders. Lab Invest 2003; 83: 107–114.10.1097/01.LAB.0000050762.61660.27CrossRef Google Scholar PubMed

Stacchini, A, Demurtas, A, Godio, L, Martini, G, Antinoro, V, Palestro, G. Flow cytometry in the bone marrow staging of mature B-cell neoplasms. Cytometry B Clin Cytom 2003; 54: 10–18.10.1002/cyto.b.10023CrossRef Google Scholar PubMed

Schniederjan, SD, Li, S, Saxe, DF, Lechowicz, MJ, Lee, KL, Terry, PD, Mann, KP. A novel flow cytometric antibody panel for distinguishing Burkitt lymphoma from CD10+ diffuse large B-cell lymphoma. Am J Clin Pathol 2010; 133: 718–726.10.1309/AJCP0XQDGKFR0HTWCrossRef Google Scholar PubMed

Miao, Y, Lin, P, Saksena, A, Xu, J, Wang, M, Romaguera, J, et al. CD5-negative mantle cell lymphoma: Clinicopathologic correlations and outcome in 58 patients. Am J Surg Pathol 2019; 43: 1052–1060.10.1097/PAS.0000000000001278CrossRef Google Scholar PubMed

Li, S, Tang, G, Jain, P, Lin, P, Xu, J, Miranda, RN, et al. SOX11+ large B-cell neoplasms: Cyclin D1-negative blastoid/pleomorphic mantle cell lymphoma or large B-cell lymphoma? Mod Pathol 2024; 37: 100405.10.1016/j.modpat.2023.100405CrossRef Google Scholar PubMed

Khanlari, M, Medeiros, LJ, Lin, P, Xu, J, You, MJ, Tang, G, et al. Blastoid high-grade B-cell lymphoma initially presenting in bone marrow: A diagnostic challenge. Mod Pathol 2022; 35: 419–426.10.1038/s41379-021-00909-4CrossRef Google Scholar PubMed

Qiu, L, Xu, J, Lin, P, Cohen, EN, Tang, G, Wang, SA, et al. Unique pathologic features and gene expression signatures distinguish blastoid high-grade B-cell lymphoma from B-acute lymphoblastic leukemia/lymphoma. Haematologica 2023; 108: 895–899.10.3324/haematol.2022.281646CrossRef Google Scholar PubMed

Accessibility standard: Inaccessible, or known limited accessibility

Why this information is here

This section outlines the accessibility features of this content - including support for screen readers, full keyboard navigation and high-contrast display options. This may not be relevant for you.

Accessibility Information

The HTML of this chapter is known to have missing or limited accessibility features. We may be reviewing its accessibility for future improvement, but final compliance is not yet assured and may be subject to legal exceptions. If you have any questions, please contact accessibility@cambridge.org.

Content Navigation

Table of contents navigation
Allows you to navigate directly to chapters, sections, or non‐text items through a linked table of contents, reducing the need for extensive scrolling.

Index navigation
Provides an interactive index, letting you go straight to where a term or subject appears in the text without manual searching.

Reading Order & Textual Equivalents

Single logical reading order
You will encounter all content (including footnotes, captions, etc.) in a clear, sequential flow, making it easier to follow with assistive tools like screen readers.

Short alternative textual descriptions
You get concise descriptions (for images, charts, or media clips), ensuring you do not miss crucial information when visual or audio elements are not accessible.

Visual Accessibility

Use of colour is not sole means of conveying information
You will still understand key ideas or prompts without relying solely on colour, which is especially helpful if you have colour vision deficiencies.

Structural and Technical Features

ARIA roles provided
You gain clarity from ARIA (Accessible Rich Internet Applications) roles and attributes, as they help assistive technologies interpret how each part of the content functions.